Pfizer (PFE)

• Market cap: $149B
• 1 day: 2.29%
• 5 days: 3.01%
• 1 month: 5.69%
• 3 months: -10.40%
• 6 months: -4.97%
• Year to date: -11.34%
• 1 year: -4.60%
• 5 years: -32.81%
• 10 years: -17.86%
• Sector: Healthcare
• Industry: Pharmaceutical Preparations

About: Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding covid-19-related product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

Employees: 88,000

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

26% more funds holding in top 10

Funds holding in top 10: 31 [Q2] → 39 (+8) [Q3]

15% more first-time investments, than exits

New positions opened: 188 | Existing positions closed: 164

3% more repeat investments, than reductions

Existing positions increased: 1,213 | Existing positions reduced: 1,175

1% more funds holding

Funds holding: 2,824 [Q2] → 2,848 (+24) [Q3]

1% less capital invested

Capital invested by funds: $108B [Q2] → $107B (-$906M) [Q3]

2.57% less ownership

Funds ownership: 67.33% [Q2] → 64.76% (-2.57%) [Q3]

38% less call options, than puts

Call options by funds: $2.51B | Put options by funds: $4.05B

Research analyst outlook

6 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $25 5% downside
• Avg. target: $33 24% upside
• High target: $45 71% upside

6 analyst ratings

• positive: 3 50%
• neutral: 2 33%
• negative: 1 17%

Truist Securities Srikripa Devarakonda 33% 1-year accuracy 10 / 30 met price target	21% upside $32	Buy Maintained	18 Dec 2024
Guggenheim Vamil Divan 40% 1-year accuracy 8 / 20 met price target	25% upside $33	Buy Maintained	11 Dec 2024
B of A Securities Tim Anderson 50% 1-year accuracy 3 / 6 met price target	10% upside $29	Neutral Reinstated	10 Dec 2024
Wolfe Research Alexandria Hammond 33% 1-year accuracy 3 / 9 met price target	5% downside $25	Underperform Initiated	15 Nov 2024
Cantor Fitzgerald Louise Chen 26% 1-year accuracy 40 / 155 met price target	71% upside $45	Overweight Reiterated	25 Oct 2024